Iatrogenic Creutzfeldt–Jakob disease in Australia: time to amend infection control measures for pituitary hormone recipients?

Alison Boyd, Genevieve M J A Klug, Colin L Masters and Steven J Collins
Med J Aust 2011; 194 (4): . || doi: 10.5694/j.1326-5377.2011.tb03794.x
Published online: 21 February 2011

In reply: We thank Solvyns and Ralston for their thoughtful and heartfelt comments and their assistance in ensuring historical accuracy regarding the issues surrounding iatrogenic Creutzfeldt–Jakob disease (CJD) risk and recipients of the Australian Human Pituitary Hormone Program (AHPHP).

  • Alison Boyd1
  • Genevieve M J A Klug1
  • Colin L Masters1,2
  • Steven J Collins1

  • 1 Australian National Creutzfeldt–Jakob Disease Registry, Department of Pathology, University of Melbourne, Melbourne, VIC.
  • 2 Mental Health Research Institute, Melbourne, VIC.


Competing interests:

The Australian National Creutzfeldt–Jakob Disease Registry is funded by the Australian Government Department of Health and Ageing. Steven Collins is the Medical Director of the CJD Support Group Network. He receives Fellowship and program grant funding from the National Health and Medical Research Council.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.